A higher FIB-4 index is associated with an increased incidence of renal failure in the general population

Eva Maria Schleicher1,2 | Simon Johannes Gairing1,2 | Peter Robert Galle1,2 | Jörn M. Schattenberg1 | Karel Kostev3 | Christian Labenz1,2

Abstract
The Fibrosis-4 index (FIB-4) is a recommended noninvasive fibrosis test in patients at risk of liver fibrosis. Chronic liver diseases are often associated with kidney diseases. This study aimed to investigate the association between FIB-4 and the development of renal failure among the general population. For this study, we used the Disease Analyzer database, which includes diagnoses and basic medical and demographic data of patients followed in general practices in Germany. Using these data, we extensively matched patients with a FIB-4 index ≥ 1.3 (n = 66,084) to patients with a FIB-4 index < 1.3 (n = 66,084). The primary outcome was the incidence of renal failure or chronic renal failure during a 10-year period. Within 10 years of the index date, 9.2% of patients with a FIB-4 < 1.3 and 10.6% of patients with a FIB-4 ≥ 1.3 were diagnosed with renal failure (p = 0.007). The endpoint chronic renal failure was reached by 7.9% with a FIB-4 < 1.3 and 9.5% with a FIB-4 ≥ 1.3 (p < 0.001). A FIB-4 index ≥ 1.3 was associated with a slight increase in renal failure incidence (hazard ratio [HR]: 1.08, p = 0.009). There was an increasing association between an increase in FIB-4 index and the incidence of renal failure with the strongest association for a FIB-4 index ≥ 2.67 (HR: 1.34, p = 0.001).

Conclusion: A higher FIB-4 index is associated with an increased incidence of renal failure. Therefore, the FIB-4 index may be useful in identifying patients who are at risk not only for liver-related events but also for renal disease.
INTRODUCTION

Patients with advanced liver fibrosis have a high risk of disease progression resulting in decompensation and an increased mortality.\[1\] Several studies are currently in progress or have been completed (e.g., LiverScreen [NCT03789825] or SEAL) to determine the best strategy for fibrosis screening in the general population.\[2,3\] As of today, liver biopsy still remains the gold standard for the grading of fibrosis. However, there is a great need for noninvasive procedures based on imaging or laboratory values because of the invasive nature of biopsy and the potential risks associated with the procedure.\[4–6\] Although liver stiffness measurement by transient elastography is a cost-effective screening tool, its availability is limited in primary care settings.\[7–9\] Another cheap alternative to estimate the risk of advanced fibrosis is the Fibrosis-4 index (FIB-4). It relies on readily available blood tests (aminotransferases and platelet count). Initially, it was developed as a noninvasive test to predict liver fibrosis in patients with human immunodeficiency virus/hepatitis C virus infection.\[10\] The European Association for the Study of the Liver recommends the implementation of the FIB-4 as a noninvasive fibrosis test in populations at risk of liver fibrosis.\[6\] There is evidence that the FIB-4 is not only relevant for hepatic diseases and liver-related events but also for extrahepatic comorbidities such as depression.\[11,12\] Given the fact that advanced liver fibrosis also appears to be linked to a higher risk of incidental chronic kidney disease (CKD), the FIB-4 may have merit to identify high-risk patients in the general population.\[13,14\] Therefore, it was the aim of this study to investigate the association between a higher FIB-4 and the incidence of renal failure over a 10-year period in the general population in Germany.

METHODS

Database

This study was based on data from the Disease Analyzer database (IQVIA), which contains drug prescriptions, diagnoses, and basic medical and demographic data obtained directly and in an anonymous format from computer systems used in the practices of general practitioners and specialists.\[15\] The database covers approximately 3% of all outpatient practices in Germany. Diagnoses (according to the International Classification of Diseases, 10th revision [ICD-10]), prescriptions (according to the Anatomical Therapeutic Chemical Classification System), and the quality of reported data are monitored by IQVIA. It has previously been shown that the panel of practices included in the Disease Analyzer database is representative of general and specialized practices in Germany.\[15\] This study population

This retrospective cohort study included adult patients (≥18 years) in 924 general practices in Germany with available laboratory values for FIB-4 calculation between January 2005 and December 2019. The index date was the first documentation of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count in this period (Figure 1). Further inclusion criteria were an observation period of at least 6 months before the index date and a follow-up time of at least 6 months after the index date. Patients with renal diseases including renal tubulo-interstitial diseases (ICD-10: N10–N16), renal failure (ICD-10: N17–N19), diabetic renal complications (ICD-10: E10.2, E11.2, E12.2, E13.2, and E14.2), and dialysis (ICD-10: Z49) before the index date were excluded.

The FIB-4 was calculated using the following formula: \( \text{age (years)} \times \frac{\text{AST (U/L)}}{\text{PLT (10}^9\text{/L}) \times \sqrt{\text{ALT (U/L)}}} \). Each patient included in the study had on average 3.2 FIB-4 values. FIB-4 was calculated per patient for the whole follow-up time. Patients with a FIB-4 of <1.3 were 1:1 matched to patients with a FIB-4 of ≥1.3 by age, sex, and diagnoses known as risk factors for renal failure (diabetes mellitus [ICD 10: E10.2–E14.2]; hypertension [ICD 10: I10–I15]; cardiovascular diseases [ICD 10: I20–I25]). The FIB-4 database has already been used in previous studies focusing on the FIB-4.\[12,16\]
E10–E14)), hypertension [ICD-10: I10], obesity [ICD-10: E66], lipid metabolism disorders [ICD-10: E78], coronary heart diseases [ICD-10: I24 and I25], and cancer [ICD-10: C00–C97]. This matching was necessary due to a very strong age, sex, and comorbidity difference among patients with a FIB-4 < 1.3 and ≥1.3. Additionally, the distribution of the three most frequent liver codes (nonalcoholic fatty liver disease [NAFLD] ICD-10: K75.8 and K76.0; chronic viral hepatitis ICD-10: B18; and liver cirrhosis ICD-10: K70.3 and K74) as well as alcohol dependency (ICD-10: F10) were displayed.

In a secondary analysis, we investigated the association between a higher AST-to-platelet ratio index (APRI) and renal failure during follow-up. The APRI was calculated using the following formula: \(\text{APRI} = \frac{\text{AST/ULN}}{\text{platelets} \times 10^9/L}.\) For these analyses, the same kind of matching process as described previously was applied.

**Study outcomes and covariates**

The primary outcome of the study was the incidence of renal failure as a function of average FIB-4 indices calculated per patient for the whole follow-up time (<1.3 vs. ≥1.3). In sensitivity analysis, we performed matching and regression analysis for other higher FIB-4 index cutoffs (<1.0 vs. ≥1.0, <1.7 vs. ≥1.7, <2.0 vs. ≥2.0). Renal failure was defined as the occurrence of either chronic renal failure (ICD-10: N18 and N19), acute renal failure (ICD-10: N17), or diabetic renal failure (ICD-10: E10.2, E11.2, E12.2, E13.2, and E14.2).

Additionally, in a second analysis, we investigated the incidence of chronic renal failure (ICD-10: N18 and N19) as a function of average FIB-4 calculated per patient for the whole follow-up time (<1.3 vs. ≥1.3). In sensitivity analysis, we performed matching and regression analysis for other FIB-4 index cutoffs (<1.0 vs. ≥1.0, <1.7 vs. ≥1.7, <2.0 vs. ≥2.0).

Finally, we investigated the incidence of renal failure as a function of average APRI calculated per patient for the whole follow-up time. Here, we performed matching and regression analysis for different APRI cutoffs (APRI ≥0.5 vs. <0.5 and ≥1.5 vs. <1.5).

**Statistical analyses**

Differences in the sample characteristics between those with a FIB-4 index <1.3 and those with a FIB-4 index ≥1.3 were tested using chi-squared tests for categorical variables and Wilcoxon tests for continuous variables. Kaplan–Meier curves were used to analyze the time to renal failure diagnosis or chronic renal failure. Univariable Cox regression models were conducted to study the ratio of two incidence rates (FIB-4 ≥1.3 vs. <1.3). Regression analyses were performed separately for women and men, four age groups (age ≤ 50, age 51–60, age 61–70, and age > 70), and patients with predefined co-diagnoses. Additionally, several sensitivity analyses for different FIB-4 cutoffs were conducted. The same analyses were also repeated for the endpoint of chronic renal failure within 10 years from the index date.

To investigate the potential association between the FIB-4 as a continuous variable and renal failure, we conducted a multivariable Cox regression model adjusted for age (as a continuous variable), sex, diabetes mellitus, hypertension, obesity, lipid metabolism disorders, coronary heart diseases, cancer, and alcohol dependency (all categorical variables).

In a secondary analysis, we conducted additional univariable Cox regression models including the dichotomized APRI to study the potential association between a higher APRI and renal failure during follow-up (APRI ≥0.5 vs. <0.5 and ≥1.5 vs. <1.5).

To counteract the problem of multiple comparisons, p-values <0.01 were considered statistically significant. Analyses were carried out using SAS version 9.4 (SAS Institute).

**RESULTS**

**Basic characteristics of the study cohort**

In total, 66,087 patients with a FIB-4 ≥ 1.3 and 66,087 matched patients with a FIB-4 < 1.3 were included.

More than 95% of patients with a FIB-4 ≥ 1.3 had a FIB-4 between 1.3 and 3.25. The baseline characteristics of study patients are displayed in Table 1. There were no significant differences in the mean age (61.4 years), sex (49% women), and the prevalence of comorbidities between both groups (Table 1). The most frequently coded underlying liver disease was NAFLD, with a frequency of 4.4% in patients with a FIB-4 < 1.3 and a frequency of 4.9% in patients with a FIB-4 ≥ 1.3.

**Incidence of renal failure**

Within 10 years of the index date, 9.2% of patients with a FIB-4 ≥ 1.3 and 10.6% of patients with a FIB-4 < 1.3 were diagnosed with renal failure (log-rank p = 0.007) (Figure 2). Of the 4925 patients with an initial renal failure diagnosis, 86.8% had chronic renal failure (ICD-10: N18 and N19), 4.0% had acute renal failure (ICD-10: N17), and 8.0% had diabetic renal failure (ICD-10: E10.2, E11.2, E12.2, E13.2, and E14.2). Dialysis was
Association of FIB-4 ≥ 1.3 and renal failure

In regression analyses, a FIB-4 ≥ 1.3 was significantly associated with an increased renal failure incidence (hazard ratio [HR]: 1.08, p = 0.009) (Table 2). In sensitivity analyses based on the same matched cohorts, a significant positive association was observed for the age group 51–60 years (HR: 1.38, p < 0.001), patients with arterial hypertension (HR: 1.15, p < 0.001), obese patients...
HEPATOLOGY COMMUNICATIONS

In another regression analysis that included the FIB-4 as a continuous variable and adjusted for these mentioned demographic characteristics and comorbidities, the association between a higher FIB-4 and renal failure remained significant (HR: 1.098 per 1-point increase in FIB-4; 95% confidence interval [CI]: 1.064–1.133; \( p < 0.001 \)) (Table S1).

In regression analyses, FIB-4 ≥ 1.3 was significantly associated with an increased chronic renal failure incidence (HR: 1.11, \( p < 0.001 \)) (Table 2). In sensitivity analyses based on the same matched cohorts, a significant positive association was observed for age groups 51–60 years (HR: 1.41, \( p < 0.001 \)) and 61–70 years (HR: 1.18, \( p = 0.001 \)), patients with diabetes (HR: 1.18, \( p = 0.011 \)), patients with arterial hypertension (HR = 1.21, \( p < 0.001 \)), obese patients (HR: 1.35, \( p < 0.001 \)), patients with lipid metabolism disorder (HR: 1.30, \( p < 0.001 \)), and patients with coronary heart disease (HR: 1.23, \( p = 0.009 \)) (Table 2).

Due to the fact that the FIB-4 is more inaccurate in the older population, and the traditional cutoffs may not apply to these patients, we repeated our sensitivity analyses in patients with age ≥ 65 years. Table 4 provides the results of regression analysis for matched pairs (≥65 years) with a FIB-4 < 1.0 versus ≥1.0, <1.7 versus ≥1.7, <2.0 versus ≥2.0, and <2.67 versus ≥2.67. There was no significant association between a FIB-4 ≥ 1.0 and chronic renal failure. The association between a FIB-4 ≥ 1.7 was very similar to that of a FIB-4 ≥ 1.3. However, a FIB-4 ≥ 2.0 was more strongly associated with chronic renal failure (HR: 1.17, \( p < 0.001 \)). The strongest association between FIB-4 and chronic renal failure was observed for a FIB-4 ≥ 2.67 (HR: 1.35, \( p < 0.001 \)).

For the analyses on the potential association between a higher APRI and renal failure, the same matching process as for the analyses on the FIB-4 were applied. In regression analyses, an APRI ≥ 0.5 (vs. 0.5) was significantly associated with an increased renal failure incidence (HR: 1.32, 95% CI: 1.23–1.41; \( p < 0.001 \)); 56,065

**Sensitivity analyses with different FIB-4 measurements for the endpoint chronic renal failure**

Table 4 lists the results of regression analyses for matched pairs with a FIB-4 < 1.0 versus ≥1.0, <1.7 versus ≥1.7, <2.0 versus ≥2.0, and <2.67 versus ≥2.67. There was no significant association between a FIB-4 ≥ 1.0 and chronic renal failure. The association between a FIB-4 ≥ 1.7 was very similar to that of a FIB-4 ≥ 1.3. However, a FIB-4 ≥ 2.0 was more strongly associated with chronic renal failure (HR: 1.17, \( p < 0.001 \)).

**Association of a FIB-4 ≥ 1.3 and chronic renal failure**

In regression analyses, FIB-4 ≥ 1.3 was significantly associated with an increased chronic renal failure incidence (HR: 1.11, \( p < 0.001 \)) (Table 2). In sensitivity analyses based on the same matched cohorts, a significant positive association was observed for age groups 51–60 years (HR: 1.41, \( p < 0.001 \)) and 61–70 years (HR: 1.18, \( p = 0.001 \)), patients with diabetes (HR: 1.18, \( p = 0.011 \)), patients with arterial hypertension (HR: 1.21, \( p < 0.001 \)), obese patients (HR: 1.35, \( p < 0.001 \)), patients with lipid metabolism disorder (HR: 1.30, \( p < 0.001 \)), and patients with coronary heart disease (HR: 1.23, \( p = 0.009 \)) (Table 2).

**Association of different APRI cutoffs and renal failure**

For the analyses on the potential association between a higher APRI and renal failure, the same matching process as for the analyses on the FIB-4 were applied. In regression analyses, an APRI ≥ 0.5 (vs. 0.5) was significantly associated with an increased renal failure incidence (HR: 1.32, 95% CI: 1.23–1.41; \( p < 0.001 \)); 56,065

**FIGURE 3** Kaplan–Meier curves for time to chronic renal failure diagnosis depending on FIB-4.
TABLE 2 Association between FIB-4 ≥ 1.3 and incident renal failure within 10 years of index date in patients followed in general practices in Germany by age and sex, and co-diagnoses (univariable regression models)

| FIB-4 ≥ 1.3 vs. <1.3 | Incidence rate ratio (95% CI) | p   |
|----------------------|-----------------------------|-----|
| Total                | 1.08 (1.02–1.14)           | 0.009|
| Age ≤50 years        | 1.33 (1.02–1.74)           | 0.039|
| Age 51–60 years      | 1.38 (1.51–1.58)           | <0.001|
| Age 61–70 years      | 1.11 (1.02–1.21)           | 0.028|
| Age >70 years        | 0.89 (0.82–0.98)           | 0.021|
| Women                | 1.05 (0.97–1.13)           | 0.228|
| Men                  | 1.10 (1.02–1.19)           | 0.014|
| Patients with diabetes| 1.07 (0.97–1.18)         | 0.193|
| Patients with arterial hypertension | 1.15 (1.06–1.25) | <0.001|
| Obese patients       | 1.25 (1.07–1.47)           | 0.005|
| Patients with lipid metabolism disorder | 1.22 (1.11–1.35) | <0.001|
| Patients with coronary heart disease | 1.14 (0.99–1.31) | 0.067|
| Patients with cancer  | 1.01 (0.85–1.20)           | 0.873|
| Patients with alcohol dependency | 1.12 (0.85–1.46) | 0.428|

Outcome: renal failure

| FIB-4 ≥ 1.3 vs. <1.3 | Incidence rate ratio (95% CI) | p   |
|----------------------|-----------------------------|-----|
| Total                | 1.11 (1.05–1.18)           | <0.001|
| Age ≤50 years        | 1.22 (0.91–1.64)           | 0.175|
| Age 51–60 years      | 1.41 (1.22–1.64)           | <0.001|
| Age 61–70 years      | 1.18 (1.07–1.29)           | 0.001|
| Age >70 years        | 0.02 (0.84–1.01)           | 0.091|
| Women                | 1.09 (1.00–1.18)           | 0.059|
| Men                  | 1.14 (1.04–1.24)           | 0.003|
| Patients with diabetes| 1.18 (1.04–1.33)        | 0.011|
| Patients with arterial hypertension | 1.21 (1.11–1.33) | <0.001|
| Obese patients       | 1.35 (1.13–1.61)           | <0.001|
| Patients with lipid metabolism disorder | 1.30 (1.16–1.46) | <0.001|
| Patients with coronary heart disease | 1.23 (1.05–1.44) | 0.009|
| Patients with cancer  | 1.06 (0.88–1.28)           | 0.528|
| Patients with alcohol dependency | 1.18 (0.88–1.59) | 0.278|

Outcome: chronic renal failure

Abbreviation: CI, confidence interval.

TABLE 3 Association between FIB-4 and incident renal failure diagnosis within 10 years of index date depending on different FIB-4 cutoffs (univariable regression models)

| FIB-4 cutoffs   | Number of matched pairs | Incidence rate ratio (higher vs. lower FIB-4) (95% CI) | p   |
|-----------------|-------------------------|-----------------------------------------------|-----|
| ≥1.0 vs. <1.0   | 73,569                  | 0.96 (0.90–1.03)                             | 0.338|
| ≥1.3 vs. <1.3   | 66,087                  | 1.08 (1.02–1.14)                             | 0.009|
| ≥1.7 vs. <1.7   | 48,033                  | 1.09 (1.03–1.15)                             | 0.003|
| ≥2.0 vs. <2.0   | 34,665                  | 1.17 (1.10–1.24)                             | <0.001|
| ≥2.67 vs. <2.67 | 14,146                  | 1.34 (1.22–1.46)                             | <0.001|

matched patient pairs). In another regression analysis including 3762 matched pairs with an APRI ≥ 1.5 or <1.5, the association with renal failure during follow-up became stronger (HR: 1.64, 95% CI: 1.23–2.18; p <0.001). The respective sensitivity and specificity of both APRI cutoffs for predicting the incidence of renal failure are displayed in Table S2.

**DISCUSSION**

In this study, we found a mild association between a higher FIB-4, a surrogate and composite score for the potential prevalence of advanced liver fibrosis, and the development of renal failure as a composite endpoint or chronic renal failure. Additionally, we were able to demonstrate an increasing association between a higher FIB-4 and the risk of renal failure or chronic renal failure during follow-up. The association between a higher FIB-4 and renal failure was more pronounced in middle-aged patients (51–60 years) and patients with metabolic comorbidities such as arterial hypertension or lipid metabolism disorders. Moreover, our findings regarding an association between noninvasive tests (NITs) for detection of liver fibrosis and renal failure were validated by secondary analyses demonstrating an additional robust association between the APRI and renal failure.

Liver diseases and especially liver cirrhosis are among the most lethal diseases worldwide, and cirrhosis itself accounts for about 2 million deaths per year.[17] Given the importance of chronic liver disease...
for overall health and prognosis, it is a surprising finding that <10% of our patients with a FIB-4 ≥ 1.3 had a coded diagnosis of chronic liver disease. In part, this may be explained by the more or less mediocre PPV of FIB-4 or other composite scores for the presence of advanced fibrosis.\(^2\) Although the FIB-4 is a validated and independent predictor of mortality and liver-related outcomes in patients with known chronic liver disease, such as NAFLD, current evidence suggests that the predictive value of the FIB-4 is not sufficient for screening of fibrosis in the general population.\(^{11,18}\) In this context, a study by Hagström et al. in the Swedish general population demonstrated that about 50% of severe liver disease outcomes had consistently low or intermediate FIB-4 values despite repeated measurements.\(^{11}\) This limited PPV of traditional NITs is confirmed by the recently published SEAL study.\(^3\) Here, only 45 of 245 participants (18.4%) with elevated aminotransferase activities and an APRI > 0.5 suffered from advanced fibrosis or liver cirrhosis after advanced diagnostic workup. Nevertheless, our findings underscore the low awareness for potentially advanced chronic liver diseases among the German population as well as physicians. This lack of awareness is a worrisome finding, as according to Schreiner et al., a FIB-4 with indeterminate risk (FIB-4 1.3–2.67) and high risk (FIB-4 >2.67) is associated with an increased incidence of severe liver disease in primary care patients without known chronic liver disease.\(^{19}\) Therefore, calculation of the FIB-4 in primary care may serve as a signal to pursue a diagnosis of chronic liver disease.\(^{20}\) In addition, there is evidence that repeating measurements of FIB-4 within a 5-year period can, in comparison with a single measurement, help to identify individuals who are at higher risk of developing severe liver disease.\(^{11}\) A Swedish epidemiological study found that an elevated FIB-4 predicted the 10-year risk of liver-related events in the general population; however, 65% of those events occurred in participants with a low FIB-4 index.\(^{21}\) Moreover, a recently published study by Shi et al. demonstrated that the FIB-4 is also associated with clinical outcomes in critically ill patients with acute kidney injury.\(^{22}\)

Our current study expands the existing literature, which focuses primarily on the predictive ability of FIB-4 regarding liver-related outcomes by demonstrating a mild association between a higher FIB-4 and key extrahepatic events such as renal failure as a composite endpoint and chronic renal failure. Although the association between a higher FIB-4 and the development of renal failure was comparably weak, the results are strengthened by a clear risk increase for renal failure in patients with a higher FIB-4. Our findings regarding the usefulness of the calculation of the FIB-4 index in a general population to predict relevant outcome measures are well in line with previous studies indicating an association between FIB-4 and

| TABLE 4 | Association between FIB-4- and incident chronic renal failure diagnosis within 10 years of index date depending on different FIB-4 cutoffs (univariable regression models) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patients ≥65 years | All patients | Number of matched pairs | Incidence rate ratio (higher vs. lower FIB-4) | (95% CI) | p | Number of matched pairs | Incidence rate ratio (higher vs. lower FIB-4) | (95% CI) | p |
| Fib-4 cutoffs | | | | | | | | |
| FIB-4 | Number of matched pairs | Incidence rate ratio (higher vs. lower FIB-4) | (95% CI) | p | Number of matched pairs | Incidence rate ratio (higher vs. lower FIB-4) | (95% CI) | p |
| ≥1.0 vs. <1.0 | 73,569 | 1.00 (0.93–1.08) | 0.978 | 9713 | 1.00 (0.93–1.08) | 0.978 | 9713 | 1.00 (0.93–1.08) | 0.978 | |
| ≥1.3 vs. <1.3 | 66,087 | 1.11 (1.05–1.18) | <0.001 | 25,663 | 1.11 (1.05–1.18) | <0.001 | 25,663 | 1.11 (1.05–1.18) | <0.001 | |
| ≥1.7 vs. <1.7 | 48,033 | 1.09 (1.04–1.16) | <0.001 | 32,992 | 1.09 (1.04–1.16) | <0.001 | 32,992 | 1.09 (1.04–1.16) | <0.001 | |
| ≥2.0 vs. <2.0 | 34,665 | 1.17 (1.10–1.24) | <0.001 | 26,380 | 1.17 (1.10–1.24) | <0.001 | 26,380 | 1.17 (1.10–1.24) | <0.001 | |
| ≥2.67 vs. <2.67 | 14,146 | 1.35 (1.22–1.48) | <0.001 | 10,778 | 1.35 (1.22–1.48) | <0.001 | 10,778 | 1.35 (1.22–1.48) | <0.001 | |
the occurrence of depression or anxiety disorders.\textsuperscript{[12]} Moreover, several studies indicated that the presence of NAFLD and especially advanced fibrosis in these patients is associated with an increased risk of developing CKD\textsuperscript{[23–27]} Seo et al. found that among patients with NAFLD, advanced liver fibrosis was associated with an increased risk of CKD, although there was no increased risk of incident CKD in the NAFLD group compared with the non-NAFLD group.\textsuperscript{[24]} Our study adds to this evidence by indicating the value of FIB-4 measurements in the general population, not only to identify patients at higher risk for liver-related events but also to identify patients at higher risk of renal failure. In this context, our data indicate that FIB-4 may have merit especially in middle-aged patients with metabolic comorbidities such as arterial hypertension or lipid metabolism disorders. Using the FIB-4 routinely in these patients could potentially help to enable screening measures to finally identify patients at an early stage of their disease.

There are well-known pathophysiological relations that link advanced fibrosis, as reflected by higher FIB-4 values, and the development of renal failure. First and foremost, advanced fibrosis is linked to (subclinical) systemic inflammation, which has a proven impact on the risk of developing renal failure.\textsuperscript{[13,28]} The underlying mechanisms are not fully understood; however, the systemic release of multiple mediators including pro-inflammatory, pro-fibrogenic, and anti-fibrinolytic molecules (e.g., fibroblast growth factor-21, tumor necrosis factor-\(\alpha\), transforming growth factor-\(\beta\)) (TGF-1\(\beta\)) can promote renal failure.\textsuperscript{[14,29–31]}

Overexpression of active TGF-1\(\beta\) in the liver of mice caused the development of severe renal fibrosis, and thus plays a key role in the development of CKD.\textsuperscript{[31–33]} Second, the renin-angiotensin-system (RAS) may constitute a potential link, as RAS activation has been implicated in the production of pro-inflammatory cytokines, in particular interleukin-6, which promotes oxidative stress.\textsuperscript{[34]} Therefore, RAS activation may support subclinical organ dysfunctions potentially leading to renal failure in the long run. Additionally, systemic and hepatic insulin resistance, atherogenic dyslipidemia, and fibrosis progression may be indicators of a decreased overall metabolic health status that feature the increased risk of the development of CKD.\textsuperscript{[25]}

Our study has several strengths such as the large patient cohort, reflecting a real-world scenario in Germany, a long follow-up period, and careful matching. Especially the large number of patients allowed us to perform sensitivity analyses and to give robust estimates of the association between FIB-4 and renal failure. However, we have to acknowledge several limitations that need to be considered when interpreting our data. First, because of our study design, we were only able to identify associations; causality has to be proven in future prospective studies. Second, our study was based on the retrospective analysis of ICD-10 codes. Therefore, we were unable to adjust for lifestyle-related factors such as chronic alcohol consumption or nutritional aspects. Moreover, we were unable to adjust our models for disease severity of comorbidities, which may be a potential bias. Additionally, there may be some bias due to undercoding or miscoding that has to be kept in mind when interpreting our data. This may be especially true for the prevalence of NAFLD. Third, some important laboratory parameters, such as creatinine or hemoglobin A1c, are only available in a small subset of our cohort. Therefore, we cannot compare the usefulness of FIB-4 for predicting renal failure with other risk factor–based models, which is a limitation. Finally, due to the fact that the follow-up period varied among individual patients, our analyses regarding the respective sensitivity and specificity of different FIB-4 and APRI cutoffs for predicting the incidence of renal failure within 10 years from the index date have to be interpreted with caution. This may introduce some bias into these analyses.

**CONCLUSIONS**

We found a mild and dose-dependent association between a higher FIB-4, a surrogate and composite score for the potential prevalence of advanced liver fibrosis, and the development of renal failure as a composite endpoint or chronic renal failure. Strikingly, the association between a higher Fib-4 and renal failure was more pronounced in middle-aged patients and patients with metabolic comorbidities such as arterial hypertension or lipid metabolism disorders. Especially in patients with metabolic comorbidities, the use of FIB-4 may help to identify patients at higher risk of renal failure.

**AUTHOR CONTRIBUTIONS**

*Research:* Eva Maria Schleicher, Karel Kostev, and Christian Labenz. *Study design and data analysis:* Eva Maria Schleicher, Karel Kostev, and Christian Labenz. *Reagents/materials/analysis tools contribution:* Karel Kostev. *Manuscript draft:* Eva Maria Schleicher, Karel Kostev, and Christian Labenz. *Critical revision of the manuscript:* Simon Johannes Gairing, Jörn M. Schattenberg, Julia Weinmann-Menke, and Peter Robert Galle. *Statistical analysis:* Karel Kostev. All authors approved the final version of the manuscript and the authorship list. Guarantor of the article: Christian Labenz.

**ACKNOWLEDGMENT**

E.M.S. and S.J.G. are supported by the Clinician Scientist Fellowship “Else Kröner Research College: 2018_Kolleg.05.” Open Access funding enabled and organized by Projekt DEAL. WOA Institution: Johannes...
CONFLICT OF INTEREST
Karel Kostev is Scientific Principal-Epidemiology Research at IMS Health (IQVIA) in Frankfurt (Germany). However, IQVIA has no influence on the content or publication of this manuscript. All other authors disclose no potential financial or nonfinancial conflicts of interest. JS consults for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Echosens, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, and Novartis. He is on the speakers’ bureau of MedPublico GmbH. He received grants from Nordic Bioscience and Siemens Healthcare GmbH. He consults and receives grants from Gilead Sciences. He consults, received grants from, and is on the speakers’ bureau of Boehringer Ingelheim.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available upon reasonable request from K.K. after approval by IQVIA.

ETHICS
This study was conducted according to the ethical guidelines of the 1964 Declaration of Helsinki (amended, 2013). We used anonymous electronic medical records for research purposes with no directly identifiable data. Accordingly, this study did not collect informed consent from individual patients, and according to German regulations no ethical approval is needed. Anonymized data were analyzed as aggregates with no protected health information available.

ORCID
Jörn M. Schattenberg https://orcid.org/0000-0002-4224-4703
Christian Labenz https://orcid.org/0000-0001-8390-9663

REFERENCES
1. Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: from fiction to reality. Best Pract Res Clin Gastroenterol. 2017;31:129–41.
2. Ginès P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, et al. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2020;72:519–28.
3. Labenz C, Arslanow A, Nguyen-Tat M, Nagel M, Wöhrs M-A, Reichert MC, et al. Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL. J Hepatol. 2022;77:695–701.
4. Chrostek L, Przekop D, Gruszewska E, Gudowska-Sawczuk M, Cylwik B. Noninvasive indirect markers of liver fibrosis in alcoholics. Biomed Res Int. 2019;2019:1–9.
5. Ratziu V, Charlotte F, Heurtler A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.
6. Berzigotti A, Tschochatsiz E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol. 2021;75:659–89.
7. Serra-Burriel M, Graupera I, Torán P, Thiele M, Roulot D, Wais Sun Wong V, et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71:1141–51.
8. Nguen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:614–25.
9. Eddowes PJ, Sasso M, Allison M, Tschochatsiz E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatois and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–30.
10. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.
11. Hagström H, Talbäck M, Andreason A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73:1023–9.
12. Schöler D, Kostev K, Garmin P, Luedde M, Konrad M, Luedde T, et al. An elevated FIB-4 score is associated with an increased incidence of depression among outpatients in Germany. J Clin Med. 2022;11:2214.
13. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638–52.
14. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in NASH. Gastroenterology. 2020;158:1913–28.
15. Rathmann W, Bongaerts B, Carius H-J, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56:459–66.
16. Loosen SH, Kostev K, Keitel V, Tacke F, Roderburg C, Luedde T. An elevated FIB-4 score predicts liver cancer development: a longitudinal analysis from 29,999 patients with NAFLD. J Hepatol. 2022;76:247–8.
17. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151–71.
18. Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, et al. Fibrosis index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol Commun. 2022;6:765–79.
19. Schreiner AD, Zhang J, Moran WP, Koch DG, Marsden J, Livingston S, et al. FIB-4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: a Fine-Gray competing risks analysis. Liver Int. 2022 May 14. https://doi.org/10.1111/liv.15295. [Epub ahead of print]
20. Roh YH, Kang B-K, Jun DW, Lee C, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep. 2021;11:13616.
21. Hagström H, Talbäck M, Andreason A, Walldius G, Hammar N. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology. 2020;158:200–14.
22. Shi Y-Y, Zheng R, Cai J-J, Fang Z-D, Chen W-J, Pan J-Y, et al. Association of FIB-4 index and clinical outcomes in critically ill patients with cirrhosis. J Hepatol. 2020;72:689–95.
ill patients with acute kidney injury: a cohort study. BMC Gastroenterol. 2021;21:483.

23. Jung C-Y, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia. 2022;65:518–27.

24. Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, et al. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J. 2022;46:630–9.

25. Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS ONE. 2014;9:e88569.

26. Zuo G, Xuan L, Xin Z, Xu Y, Lu J, Chen Y, et al. New nonalcoholic fatty liver disease and fibrosis progression associate with the risk of incident chronic kidney disease. J Clin Endocrinol Metab. 2021;106:e3957–68.

27. Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United Eur Gastroenterol J. 2020;8:942–8.

28. Li B, Haridas B, Jackson AR, Cortado H, Mayne N, Kohnken R, et al. Inflammation drives renal scarring in experimental pyelonephritis. Am J Physiol Ren Physiol. 2017;312:F43–53.

29. Li Y, Liu L, Wang B, Wang J, Chen D. Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clin Res Hepatol Gastroenterol. 2014;38:46–54.

30. Crasto C, Semba RD, Sun K, Ferrucci L. Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc. 2012;60:792–3.

31. Gu Y-Y, Liu X-S, Huang X-R, Yu X-Q, Lan H-Y. Diverse role of TGF-β in kidney disease. Front Cell Dev Biol. 2020;8:123.

32. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Investig J Tech Methods Pathol. 1996;74:991–1003.

33. Meng X, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38.

34. de Vries APJ, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2:417–26.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Schleicher EM, Gairing SJ, Galle PR, Weinmann-Menke J, Schattenberg JM, Kostev K, et al. A higher FIB-4 index is associated with an increased incidence of renal failure in the general population. Hepatol Commun. 2022;6:3505–3514. https://doi.org/10.1002/hep4.2104